{"id":"W3164197656","doi":"10.1016/s1470-2045(21)00152-2","title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":648,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; British Microcirculation Society; Novartis; Sanofi; Merck; GlaxoSmithKline; Eli Lilly and Company; AstraZeneca; Bayer; Ipsen; Clovis Oncology; Roche; Astellas Pharma US; LEO Pharma Research Foundation; Pfizer","keywords":"Medicine; Pembrolizumab; Carboplatin; Gemcitabine; Chemotherapy; Oncology; Internal medicine; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Population; Cisplatin; Cancer; Immunotherapy; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005811644,0.0005705614,0.002098113,0.00006897758,0.000369308,0.00008303918,0.0006212165,0.0002757229,0.001438344],"category_scores_gemma":[0.0001943128,0.0003299218,0.0002059412,0.0003972918,0.0002754608,0.0001316819,0.00007543431,0.0003863378,0.00003388621],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003806034,"about_ca_system_score_gemma":0.002402783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001372857,"about_ca_topic_score_gemma":0.0003532231,"domain_scores_codex":[0.9970204,0.0003269806,0.0006293426,0.0007989886,0.0003891659,0.0008350844],"domain_scores_gemma":[0.9968762,0.00111261,0.0003487494,0.001091495,0.0003303677,0.0002406166],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9276526,0.005803547,0.00003734816,0.00005685462,0.001287246,0.0002769305,0.0008339871,0.000005647238,0.003893799,0.0001607599,0.003990805,0.05600045],"study_design_scores_gemma":[0.7501925,0.08513039,0.00006577921,0.00004934283,0.0003466369,0.0002048166,0.0001166647,0.00009509153,0.02193521,0.0002919314,0.1412564,0.0003152646],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9331448,0.001136141,0.000426427,0.04724117,0.001221011,0.01184644,0.0001710134,0.0001579974,0.004654972],"genre_scores_gemma":[0.9462907,0.006003082,0.004664546,0.02766821,0.003895396,0.004209219,0.0003270334,0.0002662556,0.006675615],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1774602,"threshold_uncertainty_score":0.9999153,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1011570383933493,"score_gpt":0.4104142656501243,"score_spread":0.309257227256775,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}